Bruton’s tyrosine kinase (BTK) is at the core of present day treatment in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) which in turn is redefining first line and relapsed ...

Head-to-Head Study Highlights Rocbrutinib as the World's First Fourth-Generation Dual Covalent and Non-Covalent BTK Inhibitor Designed to Overcome Resistance Mutations ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the abstracts of two clinical studies ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical ...

BEQALZI™ (sonrotoclax) is a BCL-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) after at least two lines of systemic therapy, ...

BeOne Medicines’ sonrotoclax receives US FDA approval as first and only BCL2 inhibitor for R/R mantle cell lymphoma: San Carlos, California Saturday, May 16, 2026, 14:00 Hrs [IS ...

Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has highlighted encouraging early clinical data and fresh funding in its March 2026 quarterly report, as the company sharpens its focus on its lead CAR T ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial ...

Detailed price information for Beone Medicines Ltd (ONC-Q) from The Globe and Mail including charting and trades.

Accelerated approval of sonrotoclax establishes a targeted BCL2 option in post–BTK inhibitor relapsed/refractory mantle cell lymphoma, a setting with limited effective salvage therapies and poor ...

Detailed price information for Ascentage Pharma Group Intl ADR (AAPG-Q) from The Globe and Mail including charting and trades.

The approval is supported by results from the Phase III TULIP-SC trial.